InvestorsHub Logo
icon url

xblkbk

11/25/19 11:28 PM

#230119 RE: couldbebetter #230115

ChiBull,

Agree with your become “another low P/E BP” comment.

Reading all the takeout commentary, which will only grow more exponentially as we approach the JP Morgan Conference, people seem to forget that JT is incentivized to SELL!!

Yes, as any of us would, he will seek the maximum offer.

Until we know the broadness of the label, and thereby the off-label potential in CVD, the negotiations can’t begin. Then, discussions of Alzheimer’s (VA), NASH (GILD), Colorectal (Harvard)...for additional milestones or CVR.

The next few months will be exciting!!

x BLK BK
icon url

KCSVEN

11/26/19 6:34 AM

#230128 RE: couldbebetter #230115

Simple answer is the best offer is just not good enough. At that point GIA is the only option. Say the 2 rumors from awhile back that were out there were true. BP offered 12-13 billion, Amarin asked for 30. So if they both think that’s fair how do you get a deal, JT should just go down to 15 to get a deal? No way, can get there GIA with high odds.
BP, barring a bidding war, would not pay more than 20 billion IMO running various models. JT and board probably does that, but maybe not, maybe BP won’t go above 15.
Then you are into a BO with milestone payments which nobody really wants to do but may have to and now more complicated, complicated deals are hard.

So though BO logically is the path they seem to be heading towards it just may not transpire so they need to do everything they can to execute sales ASAP.

Good thing is management has hit on almost every decision the last year plus though I still question the amount of the last raise as cash flow should be positive next year but I get putting yourself in a good cash position. Otherwise management has proven itself very adept so far and whichever way it goes I have faith in them.